Eric Leire
Person
Dr Eric Leire is the founder and chief executive officer of Genflow Biosciences, a biotechnology company focused on developing therapies related to longevity and age-related disease. He brings pharmaceutical and biotechnology industry experience to the company and has led its work on longevity research and development.
What Eric Leire has said on podcasts
9 statements
GenFlow expects European patents within four months.
“we are now expecting the European patents from the European Patent Office within the next 4 months.”
Open the episode · S12 Ep2: The Sunday Roast featuring Genflow Biosciences, Energy Pathways and Buccaneer Energy #GENF #EPP #BUCE #INC #KEN #FMET #GMET #SVML #UOG #TGR #TAR #XTR #AFP #SRVLListen at 14:40
GenFlow’s plasmid DNA treatment was safe at both tested doses in dogs.
“the PDNA, we know it's safe. It showed that it was safe, low dose and high dose.”
Open the episode · S12 Ep2: The Sunday Roast featuring Genflow Biosciences, Energy Pathways and Buccaneer Energy #GENF #EPP #BUCE #INC #KEN #FMET #GMET #SVML #UOG #TGR #TAR #XTR #AFP #SRVLListen at 26:20
GenFlow’s trial showed biological-age reduction correlated with muscle benefit in dogs.
“this trial not only says yes, we can, we can make those dogs biologically younger and we can measure it, but we can correlate that with a biological benefit, in our case on the muscle.”
Open the episode · S12 Ep2: The Sunday Roast featuring Genflow Biosciences, Energy Pathways and Buccaneer Energy #GENF #EPP #BUCE #INC #KEN #FMET #GMET #SVML #UOG #TGR #TAR #XTR #AFP #SRVLListen at 27:26
A granted patent would materially increase GenFlow’s animal-health deal value.
“if we have a patent granted, issued, that will have a major impact on the value of the deal.”
Open the episode · S12 Ep2: The Sunday Roast featuring Genflow Biosciences, Energy Pathways and Buccaneer Energy #GENF #EPP #BUCE #INC #KEN #FMET #GMET #SVML #UOG #TGR #TAR #XTR #AFP #SRVLListen at 33:23
GenFlow’s animal-health deal valuation will exceed its market capitalization.
“the valuation of the deal will always be superior to our market cap.”
Open the episode · S12 Ep2: The Sunday Roast featuring Genflow Biosciences, Energy Pathways and Buccaneer Energy #GENF #EPP #BUCE #INC #KEN #FMET #GMET #SVML #UOG #TGR #TAR #XTR #AFP #SRVLListen at 35:16
Conditional FDA approval could positively affect GenFlow’s share price.
“it will have an impact on the market and it will have an impact on Oh well, share price.”
Open the episode · S12 Ep2: The Sunday Roast featuring Genflow Biosciences, Energy Pathways and Buccaneer Energy #GENF #EPP #BUCE #INC #KEN #FMET #GMET #SVML #UOG #TGR #TAR #XTR #AFP #SRVLListen at 38:44
GenFlow intends to license human programs after Phase 2 efficacy signals.
“our model is to license at Phase 2.”
Open the episode · S12 Ep2: The Sunday Roast featuring Genflow Biosciences, Energy Pathways and Buccaneer Energy #GENF #EPP #BUCE #INC #KEN #FMET #GMET #SVML #UOG #TGR #TAR #XTR #AFP #SRVLListen at 44:41
GenFlow expects business-development proceeds to advance three human programs.
“Getting these trade sales or business development deal will definitely allow us to move our programs, our 3 programs in humans: glaucoma, MASH, and sarcopenia.”
Open the episode · S12 Ep2: The Sunday Roast featuring Genflow Biosciences, Energy Pathways and Buccaneer Energy #GENF #EPP #BUCE #INC #KEN #FMET #GMET #SVML #UOG #TGR #TAR #XTR #AFP #SRVLListen at 45:05
GenFlow’s dog product could reach approval within one to two years.
“2 years could be, even a year with the XCA, that could be fast.”
Open the episode · S12 Ep2: The Sunday Roast featuring Genflow Biosciences, Energy Pathways and Buccaneer Energy #GENF #EPP #BUCE #INC #KEN #FMET #GMET #SVML #UOG #TGR #TAR #XTR #AFP #SRVLListen at 45:54
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
